Correction to “Circulating Levels of Galectin‐9 Are a Potential Biomarker of Survival in Advanced Non‐Small‐Cell Lung Cancer”

Filho GVdM, Costa GJ, Martins MR, Torres LC. Circulating levels of galectin-9 are a potential biomarker of survival in advanced non-small-cell lung cancer. J Surg Oncol. 2024; 130: 913-918. https://doi.org/10.1002/jso.27758. In paragraph 2.1 of the Methods section, add a third paragraph to the text “The criteria for exclusion were pregnant or lactating patients, patients with psychiatric disorders, patients with a clinical history of HIV I/II or HTLV I/II infection, patients with a clinical history of autoimmune or infectious diseases, patients with a previous diagnosis and treatment for another type of malignant tumor and patients who had undergone prior chemotherapy, immunotherapy, or radiotherapy. In paragraph 2.3 of the Methods section, remove the incorrect paragraph “A Kaplan–Meier curve with log-rank test was performed for survival time between sGal-9 ≤ 1,694 and > 1,694 groups and smoking status (smokers vs non-smokers)” and replace it with the text “The median survival time was calculated using a specific Gal9 cutoff value. The median survival using the Gal9 cutoff less than or equal to 1694 pg/mL was 15.9 months and undefined for the above cutoff point 1694 pg/mL.” We apologize for these errors.